Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence
Frontiers in Immunology, vol. 15, pp. 1368290
Abstract
Background NK cells can be genetically engineered to express a transgenic T-cell receptor (TCR). This approach offers an alternative strategy to target heterogenous tumors, as NK:TCR cells can eradicate both tumor cells with high expression of HLA class I and antigen of interest or HLA class I negative tumors. Expansion and survival of NK cells relies on the presence of IL-15. Therefore, autonomous production of IL-15 by NK:TCR cells might improve functional persistence of NK cells. Here we present an optimized NK:TCR product harnessed with a construct encoding for soluble IL-15 (NK:TCR/IL-15), to support their proliferation, persistence and cytotoxic capabilities. Methods Expression of tumor-specific TCRs in peripheral blood derived NK-cells was achieved following retroviral transduction. NK:TCR/IL-15 cells were compared with NK:TCR cells for autonomous cytokine production, proliferation and survival. NK:BOB1-TCR/IL-15 cells, expressing a HLA-B*07:02-restricted TCR against BOB1, a B-cell lineage specific transcription factor highly expressed in all B-cell malignancies, were compared with control NK:BOB1-TCR and NK:CMV-TCR/IL-15 cells for effector function against TCR antigen positive malignant B-cell lines in vitro and in vivo. Results Viral incorporation of the interleukin-15 gene into engineered NK:TCR cells was feasible and high expression of the TCR was maintained, resulting in pure NK:TCR/IL-15 cell products generated from peripheral blood of multiple donors. Self-sufficient secretion of IL-15 by NK:TCR cells enables engineered NK cells to proliferate in vitro without addition of extra cytokines. NK:TCR/IL-15 demonstrated a marked enhancement of TCR-mediated cytotoxicity as well as enhanced NK-mediated cytotoxicity resulting in improved persistence and performance of NK:BOB1-TCR/IL-15 cells in an orthotopic multiple myeloma mouse model. However, in contrast to prolonged anti-tumor reactivity by NK:BOB1-TCR/IL-15, we observed in one of the experiments an accumulation of NK:BOB1-TCR/IL-15 cells in several organs of treated mice, leading to unexpected death 30 days post-NK infusion. Conclusion This study showed that NK:TCR/IL-15 cells secrete low levels of IL-15 and can proliferate in an environment lacking cytokines. Repeated in vitro and in vivo experiments confirmed the effectiveness and target specificity of our product, in which addition of IL-15 supports TCR- and NK-mediated cytotoxicity.
Authors 7
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
-
Affiliation as printed
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Antwerp, Belgium
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Belgium
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
-
Mirjam H.M. Heemskerk corresponding Aachen Department of Hematology, Leiden University Medical Centre
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Hematology, Leiden University Medical Centre (LUMC), Leiden, Netherlands
Department of Hematology, Leiden University Medical Centre (LUMC), Netherlands
Cited by 6 stored of 6
6 results
No patents citing this paper on Lens.org (checked 2026-10-11).